Information Provided By:
Fly News Breaks for January 10, 2017
MDRX
Jan 10, 2017 | 08:22 EDT
Maxim analyst Anthony Vendetti lowered his 2017 and 2018 EPS estimates for Allscripts after the company gave its preliminary outlook for Q4 and 2017. He cut his price target on the shares to $16 from $18 to account for the lowered view, but he maintains a Buy rating, saying the company announced strong preliminary bookings and the shares have an attractive valuation.
News For MDRX From the Last 2 Days
There are no results for your query MDRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.